title: Alectinib in RET-rearranged non-small cell lung cancer-Another progress in precision medicine?
abstract: RET fusions have been recognized as potential therapeutic targets in advanced non-small cell lung cancer. RET fusion proteins are detected in about 2% of lung adenocarcinomas. Alectinib, a second generation ALK inhibitor, was shown to block growth of cells with RET fusions. Thus alectinib should be further evaluated within clinical trials in patients with RET fusion-positive adenocarcinomas of the lung.
authors.affiliation: Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria.
authors.forename: Robert
authors.initials: R
authors.lastname: Pirker
authors.affiliation: Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria.
authors.forename: Martin
authors.initials: M
authors.lastname: Filipits
keywords: Alectinib; RET; biomarker; targeted therapy; tyrosine kinase inhibitor